xten peptide Glucagon-like peptide 2 (GLP2 - Multivalent antiviralxten peptideconjugates with long in vivo half life and enhanced solubility peptides Unlocking Extended Therapeutic Potential: The Science Behind XTEN Peptides

Multivalent antiviralxten peptideconjugates with long in vivo half life and enhanced solubility The field of therapeutic drug development is constantly seeking innovative ways to enhance the efficacy and duration of treatment. A significant area of focus is extending the in vivo half-life of peptides and proteins, allowing for less frequent dosing and potentially improved patient outcomes作者：C Harrison·2010—Initial characterization studies showed thatexenatide–XTENwas a homogeneous chemical species that was not strongly immunogenic and showed no adverse effects .... Emerging as a powerful tool in this pursuit is XTEN, a class of unstructured, hydrophilic, and biodegradable protein polymers that mimic some of the beneficial properties of polyethylene glycol (PEG), while offering unique advantages作者：VN Podust·2013·被引用次数：56—XTEN, unstructured biodegradable proteins, have been used to extend the in vivo half-life of genetically fused therapeutic proteins andpeptides..

XTEN is not a single entity but rather a versatile technology. It's described as a polypeptide constructed from specific hydrophilic amino acid building blocks, including alanine (A), glutamic acid (E), glycine (G), proline (P), serine (S), and threonine (T).作者：S Ding·2014·被引用次数：80—XTENs areunstructured, nonrepetitive protein polymersdesigned to prolong the in vivo half-life of pharmaceuticals by introducing a bulking effect similar ... This carefully selected composition imbues XTEN with desirable characteristics such as a large hydrodynamic volume and a negative charge, contributing to its ability to significantly prolong the circulation time of fused molecules. Researchers have explored various XTEN sequences and lengths, such as the notable XTEN864-HGV-Apoptin fusion protein, to optimize these properties.

The primary application of XTEN lies in its role as a linker or a fusion partner. By genetically fusing an XTEN polypeptide to a peptide or protein drug, scientists can create novel conjugates with extended therapeutic activity. This process, often referred to as XTENylation, has demonstrated the ability to increase the half-life of molecules by as much as 60- to 130-fold over their native counterparts, as seen with exenatide–XTEN conjugates. This remarkable extension is attributed to the bulking effect that the XTEN polypeptide imparts, shielding the fused therapeutic from rapid clearance by the body's natural elimination mechanisms.

The advantages of XTEN over traditional PEGylation are manifold.Extension of in vivo half-life of biologically active peptides ... Unlike PEG, which is a synthetic polymer, XTEN is a protein-based material produced through recombinant technology. This means it can be manufactured with high purity and controlled sequences, leading to greater consistency and potentially reduced immunogenicityA recombinant polypeptide extends the in vivo half-life of .... Studies have indicated that XTEN peptide conjugates are generally safe and non-immunogenic in various animal species.作者：C Harrison·2010—Initial characterization studies showed thatexenatide–XTENwas a homogeneous chemical species that was not strongly immunogenic and showed no adverse effects ... Furthermore, XTEN is biodegradable, meaning it is naturally broken down by the body, which can be a significant advantage for long-term therapeutic applications.

The versatility of XTEN is evident in its application across a broad spectrum of biologically active moleculesPeptides: Types, Applications, Benefits & Safety - WebMD. It has been successfully used to enhance the in vivo half-life of therapeutic peptides, imaging probes like annexin A5, and even complex proteins作者：A Haeckel·2014·被引用次数：36—So far,XTEN peptidehas been shown to be safe and nonimmunogenic in several animal species (7) and 2 XTEN-modified drugs have entered .... This broad applicability makes XTEN a valuable platform for developing next-generation therapeutics. For instance, research into Glucagon-like peptide 2 (GLP2) has seen the development of GLP2-2G-XTEN, showcasing improved pharmacological profiles.2025年8月6日—We show that genetic fusion of an unstructured recombinantpolypeptideof 864 amino acids, calledXTEN, to apeptideor protein provides an ... Similarly, exploring novel long-acting glucagon-like peptide-1 (GLP-1) therapies often involves strategies like the XTEN polypeptide to achieve sustained release.XtenCHO™ Race Transient Expression System

Beyond therapeutic half-life extension, XTEN is also being explored for its potential in creating advanced biomaterialsData suggest that chemical XTENylation could effectively extend the half-life of a wide spectrum of biologically active molecules, therefore broadening its .... Genetically encoded XTEN-based hydrogels, for example, are being developed with tunable properties, demonstrating the material's adaptability for various biomedical applications.

The development of XTEN technology, pioneered by companies like Amunix, represents a significant advancement in drug delivery. Amunix's proprietary protein-based polymer, XTEN, mimics the biophysical properties of PEG and is used to extend the half-life of therapeutics.Critical aspects of peptide hormone abuse in exercise and sports The extended recombinant polypeptide (XTEN) compositions and conjugate strategies offer a robust method for drug developers. This innovation is contributing to the development of multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility, opening new avenues for treating infectious diseases.

In summary, XTEN is a groundbreaking polypeptide technology that offers a unique and powerful approach to extending the circulatory half-life of therapeutic agents. Its protein-based nature, biodegradability, and tunable properties make it an attractive alternative to existing technologies like PEGylation. As research continues, XTEN is poised to play a crucial role in the development of more effective and convenient treatments across a wide range of diseases, potentially leading to improved patient care and outcomes. The ability to create XTEN protein and XTEN polymer constructs with defined characteristics ensures its continued relevance in the evolving landscape of biopharmaceutical innovation.